What is the recommended treatment protocol for a patient with confirmed COVID‑19, including outpatient antiviral therapy for high‑risk patients and inpatient management for moderate to severe disease?

COVID-19 Treatment Protocol

Outpatient Management for High-Risk Patients

For symptomatic outpatients with confirmed COVID-19 who are at high risk for disease progression and within 5 days of symptom onset, nirmatrelvir/ritonavir (300 mg/100 mg orally every 12 hours for 5 days) is the preferred antiviral therapy. 1, 2

Risk Stratification and Treatment Selection

High-risk patients (those with significant comorbidities, age ≥65 years, immunocompromised status, or unvaccinated):

• First-line: Nirmatrelvir/ritonavir - provides high certainty evidence of important reduction in hospitalization and moderate certainty of survival benefit 1
• Alternative: Molnupiravir (800 mg orally every 12 hours for 5 days) if nirmatrelvir/ritonavir is contraindicated due to drug interactions or unavailable 1, 2
• Third option: Remdesivir (intravenous) if oral agents cannot be used, though less practical due to parenteral administration 1, 3

Moderate-risk patients:

• Nirmatrelvir/ritonavir may be considered, though benefits are smaller than in high-risk patients 1

Low-risk patients:

• Antivirals are not recommended as benefits are trivial 1

Critical Prescribing Considerations

Drug interactions with nirmatrelvir/ritonavir are extensive and must be carefully evaluated - ritonavir affects metabolism and clearance of many medications during treatment and for several days after completion 1. Use the Liverpool COVID-19 drug interaction tool before prescribing 1.

Dose adjustments: For patients with estimated glomerular filtration rate 30-59 mL/min, reduce nirmatrelvir/ritonavir to 150 mg/100 mg orally every 12 hours for 5 days 1.

Treatments NOT Recommended for Outpatients

Do not use the following in outpatient COVID-19 management:

• Ivermectin 1, 3, 2
• Hydroxychloroquine 1, 3
• Azithromycin (unless bacterial infection present) 1, 3
• Sotrovimab (ineffective against current variants) 1, 3, 2
• Convalescent plasma 3
• Corticosteroids (reserved for hospitalized patients requiring oxygen) 1

---

Inpatient Management for Moderate to Severe Disease

Oxygen Requirements Define Treatment Strategy

For hospitalized patients requiring supplemental oxygen, noninvasive ventilation, or mechanical ventilation:

Corticosteroids are strongly recommended - dexamethasone 6 mg daily reduces mortality in patients requiring oxygen support (29.3% vs 41.4% mortality in mechanically ventilated patients) 1

Do NOT use corticosteroids in hospitalized patients not requiring supplemental oxygen - no mortality benefit demonstrated and potential for harm 1

Immunomodulatory Therapy

IL-6 receptor antagonists (tocilizumab, sarilumab) should be considered for hospitalized patients requiring oxygen or ventilatory support, particularly those with evidence of systemic inflammation 1

JAK inhibitors (baricitinib) can be added to corticosteroids in patients with severe or critical COVID-19 for additional benefit 1

Antiviral Therapy in Hospitalized Patients

Remdesivir may be considered for hospitalized patients not requiring mechanical ventilation, though evidence is moderate quality 1

Do NOT use remdesivir in patients requiring invasive mechanical ventilation - conditional recommendation against use in this population 1

Anticoagulation Management

All hospitalized COVID-19 patients should receive prophylactic anticoagulation with low-molecular-weight heparin (LMWH) to reduce thrombotic complications 1

For patients with pre-existing anticoagulation indications:

• Continue dual antiplatelet therapy (DAPT) in patients with recent acute coronary syndrome alongside prophylactic-dose anticoagulation 1
• Continue antiplatelet therapy in stroke patients and add prophylactic-dose LMWH 1
• Switch oral anticoagulation to therapeutic-dose LMWH or unfractionated heparin in hospitalized patients with atrial fibrillation if oral agents must be discontinued 1

New-onset atrial fibrillation: Start therapeutic-dose parenteral anticoagulation in all hospitalized patients regardless of CHA2DS2-VASc score 1

Respiratory Support

High-flow nasal cannula (HFNC) or noninvasive CPAP (via helmet or facemask) should be used for patients with hypoxemic respiratory failure without immediate indication for intubation 1

Special Populations

Pregnant and breastfeeding patients with non-severe COVID-19 may consider nirmatrelvir/ritonavir, though uncertainty exists regarding potential adverse reactions 1

Immunocompromised patients and those with hematological malignancies:

• Consider monoclonal antibodies for pre-exposure or post-exposure prophylaxis in high-risk patients 1
• Maintain growth factor support to keep absolute neutrophil count >1000 cells/µL, though reconsider in moderate-to-severe COVID-19 due to potential pulmonary complications 1
• Test for SARS-CoV-2 before initiating chemotherapy; if positive, delay treatment 10-14 days when possible 1